Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Polycystic Ovary Syndrome 1Non-alcoholic Fatty Liver Disease 1Lung Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

Cisplatin 38Carboplatin 28Gemcitabine 23Docetaxel 20Radiotherapy 18Etoposide 15Paclitaxel 13Erlotinib Hydrochloride 13Vinorelbine 11Drug Therapy 11pembrolizumab 9aumolertinib 9apatinib 9Pemetrexed 9Gefitinib 9osimertinib 7endostar protein 7Thoracic Surgery, Video-Assisted 7Blood Specimen Collection 7camrelizumab 6anlotinib 6Vinblastine 6Surgical Procedures, Operative 6sintilimab 5Radiosurgery 5Fluorodeoxyglucose F18 5Cyclophosphamide 5Bevacizumab 5durvalumab 4Mitomycin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lung Neoplasms × Canagliflozin × Clear all
NCT04073680 2020-05-21

A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors

Petra Pharma

Phase 1/2 Unknown
60 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡